Archive for July, 2012

Drug Patent Expirations for Jun 25 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

<TD align=right–>
ADVERTISE
HERE
Who are the leading pharmaceutical patent challengers? A report on<br />
Paragraph IV challenges<!–/td>

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for June 25 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
EDARBI Takeda Pharms azilsartan
kamedoxomil
5,736,555 Jun 25, 2012
EDARBYCLOR Takeda
Pharms
azilsartan kamedoxomil; chlorthalidone 5,736,555 Jun 25,
2012
NEORAL Novartis cyclosporine 6,258,808 Jun 25,
2012
NEORAL Novartis cyclosporine 6,262,022 Jun 25,
2012

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Continue reading

Cayman Enterprise City Delegation Travels to London

Cayman Enterprise City (CEC) delegation spends week in London reaching out to potential channel partners and clients in the United Kingdom. CEC, the Western Hemisphere’s only knowledge-based Special…(PRWeb July 04, 2012)Read the full story at ht…


Chitinor AS of Norway Reaches Agreement with BASF SE to Acquire…

Chitinor AS has reached an agreement with BASF SE to acquire BASFs marine biopolymers chitosan business operations. The deal marks a strategic milestone for Chitinor’s business development plans for…(PRWeb July 04, 2012)Read the full story at ht…


Drug Patent Expirations for Jun 20 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

FDA Orange Book archives from 2005 to<br />
present
ADVERTISE
HERE

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for June 20 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
CHILDREN’S
MOTRIN
Mcneil ibuprofen 5,374,659*PED Jun
20, 2012
CHILDREN’S
MOTRIN
Mcneil Cons ibuprofen 5,374,659*PED Jun
20, 2012
MOTRIN Mcneil
Consumer
ibuprofen 5,374,659*PED Jun
20, 2012

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.

Share this:


Continue reading

Drug Patent Expirations for Jun 29 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Journal of Commercial Biotechnology
ADVERTISE
HERE

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for June 29 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
EMEND Merck aprepitant 6,048,859 Jun 29,
2012
EMEND Merck aprepitant 6,235,735 Jun 29,
2012

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Continue reading

ISPE Releases New Guidance for Designing and Constructing Packaging,…

New Guide helps companies meet CGMP requirements and avoid product adulteration, product mix-up, label mix-up and misbranding.(PRWeb July 03, 2012)Read the full story at http://www.prweb.com/releases/2012/7/prweb9666951.htm


Continue reading

Drug Patent Expirations in July 2012

This information is also available in an email newsletter: Subscribe to the . Courtesy of


Continue reading

Soliant Names 2012 Top 20 Most Beautiful Hospitals in America

Martha Jefferson Hospital Takes Top Honor(PRWeb July 03, 2012)Read the full story at http://www.prweb.com/releases/2012/7/prweb9664625.htm


Continue reading

NexDx Co-Founder Gary S. Firestein Publishes Findings that Epigenetics…

The scientific discoveries that led to the founding of the science driven molecular diagnostics company NexDx, Inc. (http://www.nexdx.com) in 2011 in San Diego are…(PRWeb July 03, 2012)Read the full story at http://www.prweb.com/releases/2012/7/pr…


Continue reading

July is not just about BBQ's; the Arthritis National Research…

The Arthritis National Research Foundation is reminding people that July is not just about barbeques and the beach. July represents Juvenile Arthritis Awareness month. Arthritis affects nearly 300,000…(PRWeb July 03, 2012)Read the full story at ht…


Continue reading